Cash Falls Sharply as Ensysce Biosciences Reports Widening Q1 Net Loss
ENSC sits 21% above its 52-week low of $0.23 on light trading volume (0.1× avg).
Summary
Ensysce Biosciences reported a significant widening of its Q1 net loss to $3.60 million, accompanied by a sharp decline in its cash position. The increased loss was primarily driven by higher external research and development costs associated with Phase 3 clinical trial activity for PF614, while federal grant funding also decreased. This financial update is critical for the micro-cap biotech, as a substantial cash burn raises concerns about its operational runway and ability to sustain its costly R&D pipeline, especially given the expectation of continued losses. Traders will be closely watching for any future financing announcements or updates on cash management strategies.
At the time of this announcement, ENSC was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.23 to $2.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.